---
category: trading
circular_id: 7651a69d6f50521f
date: '2025-12-18'
description: Vivimed Labs Limited (VIVIMEDLAB) will be transferred from BE series
  to EQ series effective December 26, 2025.
draft: false
guid: https://nsearchives.nseindia.com/content/circulars/CML71870.pdf
impact: medium
impact_ranking: medium
importance_ranking: medium
justification: Transfer from BE to EQ series indicates improved compliance status
  for Vivimed Labs, affecting trading conditions and investor access
pdf_url: https://nsearchives.nseindia.com/content/circulars/CML71870.pdf
processing:
  attempts: 1
  content_hash: 874986a6690e6302
  processed_at: '2025-12-18T12:57:51.200545'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-12-18T00:00:00+05:30'
rss_url: https://nsearchives.nseindia.com/content/circulars/CML71870.pdf
severity: medium
source: nse
stocks:
- VIVIMEDLAB
tags:
- series-transfer
- be-series
- eq-series
- trading
- vivimed-labs
title: Transfer of Vivimed Labs Limited from BE Series to EQ Series
---

## Summary

NSE has announced the transfer of trading in securities of Vivimed Labs Limited (Symbol: VIVIMEDLAB) from the BE (Book Entry) series to the EQ (Equity) series, effective December 26, 2025. This transfer is pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

## Key Points

- Company: Vivimed Labs Limited
- Symbol: VIVIMEDLAB
- Transfer: From BE series to EQ series
- Effective Date: December 26, 2025
- Circular Reference: NSE/CML/71870, Circular No. 2469/2025
- Regulatory Framework: SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

## Regulatory Changes

The transfer from BE series to EQ series represents a change in the trading category for Vivimed Labs Limited. The BE series typically includes securities under enhanced surveillance or those not meeting certain compliance requirements, while the EQ series represents normal equity trading. This transfer indicates that the company has met the necessary criteria to move to standard equity trading.

## Compliance Requirements

- Exchange members must note the series change for Vivimed Labs Limited
- Trading systems should be updated to reflect the new EQ series classification
- All trading in VIVIMEDLAB must be conducted in EQ series from December 26, 2025 onwards

## Important Dates

- **Circular Date**: December 18, 2025
- **Effective Date**: December 26, 2025

## Impact Assessment

The transfer from BE to EQ series is a positive development for Vivimed Labs Limited, indicating improved compliance and corporate governance standards. This change may:

- Improve liquidity as EQ series typically attracts more institutional investors
- Reduce trading restrictions associated with BE series
- Enhance investor confidence in the security
- Potentially reduce margin requirements for traders
- Allow broader participation in the stock as surveillance measures are relaxed